- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
GI Cancers | Clinical
Divergent Resistant Mechanisms Found With Upfront anti-EGFR Therapy in mCRC
October 05, 2022
Analysis from the phase 3 CALGB/SWOG-80405 trial reveals that acquired genomic alterations in patients treated with cetuximab in combination with chemotherapy in the first-line were not common.
FDA Approves Futibatinib for FGFR2+ Advanced Cholangiocarcinoma
September 30, 2022
Findings from the TAS-120-101 study have led the FDA to approve futibatinib for the treatment of patients with FGFR2-positive advanced cholangiocarcinoma.
Increasing Burden of Early-Onset Appendiceal Cancer
September 19, 2022
Andreana Holowatyj, PhD, MSCI, discusses the rationale for her research on the growing increase of early-onset appendiceal cancer in the United States.
Study of Onvansertib Plus SOC in Metastatic Colorectal Cancer Enters Phase 2
September 19, 2022
Following reports of durable response in a phase 1 study, the combination of onvansertib FOLFIRI, and bevacizumab will be evaluating in a phase 2 study of patients with metastatic colorectal cancer.
RLY-4008 Shows DCR of 100% in FGFR+ Cholangiocarcinoma
September 11, 2022
A novel FGFR inhibitor, RLY-4008, induced high response rates and encouraging durability in patients with FGFR inhibitor–naïve cholangiocarcinoma harboring an FGFR2 fusion or rearrangement, according to data from the phase 1/2 ReFocus trial presented at the 2022 ESMO Congress.
FDA Grants Approval to Durvalumab Plus Chemotherapy for Locally Advanced or Metastatic Biliary Tract Cancer
September 02, 2022
The FDA has approved durvalumab for the treatment of patients with locally advanced or metastatic biliary tract cancer.
ISGIO® Seeks to Clarify Gastrointestinal Cancer Updates for the Clinic
August 31, 2022
During the Annual Meeting of the International Society of Gastrointestinal Oncology, experts in the field and investigators from pivotal studies will elucidate how these advances can be used to guide treatment, and how to choose between available treatments in specific patient populations.
Age of Diagnosis Influences Risk Factors in Pancreatic Cancer
August 30, 2022
In an interview with Targeted Oncology, Chen Yuan, MD, further discussed the research on the age-dependent associations and risks for patients with pancreatic cancer.
MAGNOLIA Study of Abelacimab for Cancer-Associated Thrombosis Initiates Recruitment
August 30, 2022
The phase 3 MAGNOLIA study has begun enrolling patients to examine abelacimab for the treatment of thrombosis associated with cancer.
Two Genes Predict Resistance to ICIs in dMMR/ MSI-H GI Cancers
August 29, 2022
Two genes to assist in determining primary resistance to immunotherapy for patients with mismatch repair–deficient/microsatellite instability–high gastrointestinal cancers have been identified.